We analyzed APP processing by measuring the levels of its soluble non-amyloidogenic fragments (sAPPα and sAPPβ) and amyloid-β (Aβ peptides), together with GDNF levels, in cerebrospinal fluid (CSF) and serum from ALS patients and healthy controls. Here, GDNF is linked to amyotrophic lateral sclerosis.